For the development of the new biomarker using the technique of Mass-spectometry a dry blood spot filter card are taken. To prove the correct diagnosis in those patients where up to the enrollment in the study no genetic testing has been done, sequencing will be done. The analyses are done in the Centogene AG, Schillingallee 68, 18055 Rostock (Germany)